Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Foreign Corrupt Practices Act: Device Industry Under Scrutiny

This article was originally published in The Gray Sheet

Executive Summary

Federal prosecutors have begun targeting medical device companies in Foreign Corrupt Practices Act investigations

You may also be interested in...



US DoJ Won’t Prosecute Many Self-Reported FCPA Violations

Revisions to DoJ guidelines will let companies off the hook for self-reported overseas bribery charges in many cases. But whether or not to come forward remains a tricky decision.

Translating The Foreign Corrupt Practices Act Into Practice: DOJ/SEC Offer Pragmatic Enforcement Guide

The FCPA resource guide gives examples of cases the DOJ and SEC have decided not to prosecute and describes the hallmarks of an effective compliance program. AdvaMed was among groups that asked for more clarity.

News In Brief

Syneron buys UltraShape. Smith & Nephew settles foreign bribery charges. Hospitals settle kyphoplasty allegations. More news briefs.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel